| Lymphocytic Neoplasm studied in …STUDIED_INderived10 of 9,160show all (up to 200) |
|---|
| → studied in | NCT00423644Phase 2 · completed A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b · condition mapped CURATED_EXACT · 9,160 trials mapped (2,594 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00592163Phase 1 · completed Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas · condition mapped ONTOLOGY_EXACT · 9,160 trials mapped (2,594 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01414855Phase 2 · completed A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) · condition mapped CURATED_BROADER · 9,160 trials mapped (2,594 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01559935Phase 2 · completed Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma · condition mapped CURATED_EXACT · 9,160 trials mapped (2,594 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01896999Phase 1/Phase 2 · active not recruiting Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · condition mapped CURATED_BROADER · 9,160 trials mapped (2,594 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped CURATED_BROADER · 9,160 trials mapped (2,594 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03739814Phase 2 · recruiting Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 9,160 trials mapped (2,594 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 9,160 trials mapped (2,594 active) | — | — | Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05228470Phase 2 · completed A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. · condition mapped ALIAS · 9,160 trials mapped (2,594 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05354557Phase 2 · active not recruiting Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) · condition mapped CURATED_EXACT · 9,160 trials mapped (2,594 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |